Pharma company Venus Remedies Ltd today said it has filed its fifth International Patent application for its latest antibiotic fixed dose combination used in the treatment of Cystis Fibrosis.
The new antibiotic combination, active against multi-resistant strains of both gram- positive and gram-negative bacteria and provides a broad-spectrum coverage of bactericidal activity, it informed the Bombay Stock Exchange.
The fixed dose combination was developed by company's R&D centre and it had filed the Indian patent for this product, titled "Treatment and Control of severe infections, including Cystis Fibrosis", in May 2005, it said.
Cystis Fibrosis is a common hereditary disease that affects the entire body, causing progressive disability and early death.
The global market for the antibiotic is worth 500 million dollar, it added.